Search

Search Constraints

You searched for: Author/Creator Manolakopoulos, Spilios

Search Results

2. Correction: DARING-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Issue 8 (November 2018)

3. DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B. Issue 8 (November 2018)

4. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece. Issue Volume 33:Issue S1(2021) (21st May 2021)

5. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience. Issue 1 (January 2017)

6. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen‐negative chronic hepatitis B. (26th April 2017)

7. Hepatocellular carcinoma after treatment cessation in non‐cirrhotic HBeAg‐negative chronic hepatitis B: A multicentre cohort study. (20th December 2021)

8. HERACLIS‐TAF: a multi‐centre prospective cohort study on 2‐year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. Issue 4 (23rd June 2022)

9. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg‐negative chronic hepatitis B. Issue 6 (27th February 2019)

10. Long‐term clinical outcome of HBeAg‐negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. (29th December 2020)